<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156052">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068262</url>
  </required_header>
  <id_info>
    <org_study_id>0822-059</org_study_id>
    <secondary_id>2010_508</secondary_id>
    <secondary_id>MK-0822-059</secondary_id>
    <nct_id>NCT01068262</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Odanacatib (0822-059)</brief_title>
  <official_title>A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Odanacatib (MK0822) in Healthy Male and Postmenopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked
      telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0-168 hours) of Odanacatib</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and C168hr of Odanacatib</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Odanacatib</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Odanacatib administered weekly for 4 consecutive weeks, measured by number of clinical and laboratory adverse experiences</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Panel A - Odanacatib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel A - Healthy male subjects receiving Odanacatib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Panel A - Healthy male subjects receiving placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Odanacatib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel B - Healthy female subjects receiving Odanacatib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Panel B - Healthy female subjects receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Odanacatib</intervention_name>
    <description>Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks</description>
    <arm_group_label>Panel A - Odanacatib</arm_group_label>
    <arm_group_label>Panel B - Odanacatib</arm_group_label>
    <other_name>MK0822</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Oral Placebo tablet administered once weekly for 4 consecutive weeks</description>
    <arm_group_label>Panel A - Placebo</arm_group_label>
    <arm_group_label>Panel B - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male subject between the ages of 50 and 75 years; post menopausal female subjects
             between the ages of 45 and 75 years

          -  Subject is in good general health

          -  Subject has no evidence of metabolic bone disorder other than osteopenia or
             osteoporosis

          -  Subject is a non-smoker

        Exclusion Criteria:

          -  Subject works night shift and is unable to avoid nightshift work during the study

          -  Subject has had major surgery, donated blood or participated in another
             investigational study with in the past 4 weeks

          -  Subject has a history of stroke, chronic seizures, or major neurological disease

          -  Subject has a history of cancer

          -  Subject consumes excessive amounts of alcohol or caffeine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Anderson MS, Gendrano IN, Liu C, Jeffers S, Mahon C, Mehta A, Mostoller K, Zajic S, Morris D, Lee J, Stoch SA. Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women. J Clin Endocrinol Metab. 2014 Feb;99(2):552-60. doi: 10.1210/jc.2013-1688. Epub 2013 Nov 25.</citation>
    <PMID>24276460</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 1, 2015</lastchanged_date>
  <firstreceived_date>February 11, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
